Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.66 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2748126 | 0.91 | HSD11B1 (0.71) | HSD11B1P2RX7PDE2APDE10A | |
| SCHEMBL2748146 | 0.90 | HSD11B1 (0.82) | HSD11B1P2RX7PDE2APDE10A | |
| SCHEMBL2747997 | 0.81 | HSD11B1 (0.58) | HSD11B1P2RX7PDE2APDE10A | |
| SCHEMBL2747473 | 0.80 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL8819360 | 0.78 | P2RX7 (0.46) | HSD11B1P2RX7PDE2APDE10A | |
| SCHEMBL2747248 | 0.78 | HSD11B1 (0.78) | HSD11B1PDE2APDE10A | |
| SCHEMBL15206947 | 0.75 | HSD11B1 (0.69) | HSD11B1 | |
| SCHEMBL21303108 | 0.74 | HSD11B1 (0.52) | HSD11B1 | |
| SCHEMBL2748888 | 0.74 | HSD11B1 (0.81) | HSD11B1 | |
| SCHEMBL2748325 | 0.74 | HSD11B1 (0.70) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | claimed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | claimed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | claimed |
| EP-1732904-A4 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO INC (US) | 2007-11-14 | — | — | EP | claimed |
| EP-1732904-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | Merck & Co., Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097759-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK & CO., INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-8178546-B2 | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | MERCK SHARP & DOHME (US) | 2010-10-07 | — | — | US | disclosed |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME CORP. | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256387-A1 | DIARYLTRIAZOLES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885P2RX7 4271/4885PDE2A 933/4885 |
| US-20080255216-A1 | Diaryltriazoles as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885P2RX7 4347/4885PDE2A 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.